ArticleProceedings of the National Academy of Sciences of the United States of America1998
Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 56 citations in OpenAlex.
- Analysis of SLC genes alternative splicing identifies the SLC7A6 RI isoform as a therapeutic target for colorectal cancer.Cancer science · 2025Article
- Genome-wide association study of body fat distribution traits in Hispanics/Latinos from the HCHS/SOL.Human molecular genetics · 2021Article
- CDKN1C as a prognostic biomarker correlated with immune infiltrates and therapeutic responses in breast cancer patients.Journal of cellular and molecular medicine · 2021Article
- Knockdown of Orphan Transporter SLC22A18 Impairs Lipid Metabolism and Increases Invasiveness of HepG2 Cells.Pharmaceutical research · 2019Article
- Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.Cancer gene therapy · 2018Article
- Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer.Oncotarget · 2015Article
- In vitro and in vivo radiosensitization of human glioma U251 cells induced by upregulated expression of SLC22A18.Cancer gene therapy · 2014Article
- Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy.Journal of translational medicine · 2013Article
- The histone methyltransferase SUV39H1 suppresses embryonal rhabdomyosarcoma formation in zebrafish.PloS one · 2013Article
- Rhabdomyosarcomas: an overview on the experimental animal models.Journal of cellular and molecular medicine · 2012Review
- Caveolins in rhabdomyosarcoma.Journal of cellular and molecular medicine · 2011Review
- Elevated expression of solute carrier family 22 member 18 increases the sensitivity of U251 glioma cells to BCNU.Oncology letters · 2011Article
- Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma.Journal of translational medicine · 2011Article
- Effects of RAS on the genesis of embryonal rhabdomyosarcoma.Genes & development · 2007Article
- Tumor suppressor candidate TSSC5 is regulated by UbcH6 and a novel ubiquitin ligase RING105.Oncogene · 2006Article
- Paternal imprinting of the SLC22A1LS gene located in the human chromosome segment 11p15.5.BMC genetics · 2004Article
- Impaired expression of an organic cation transporter, IMPT1, in a knockout mouse model for kidney stone disease.Urological research · 2003Article
- Article
- Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas.Proceedings of the National Academy of Sciences of the United States of America · 2000Article
- Genomic imprinting: implications for human disease.The American journal of pathology · 1999Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
Abstract
Chromosome region 11p15.5 harbors unidentified genes involved in neoplasms and in the genetic disease Beckwith-Wiedemann syndrome. The genetic analysis of a 170-kb region at 11p15.5 between loci D11S601 and D11S679 resulted in the identification of six transcriptional units. Three genes, hNAP2, CDKN1C, and KVLQT1, are well characterized, whereas three genes are novel. The three additional genes were designated BWR1A, BWR1B, and BWR1C. Full-length cDNAs for these three genes were cloned and nucleotide sequences were determined. While our work was in progress, BWR1C cDNA was described as IPL [Qian, N., Franck, D., O'Keefe, D., Dao, D. , Zhao, L., Yuan, L., Wang, Q., Keating, M., Walsh, C. & Tycko, B. (1997) Hum. Mol. Genet. 6, 2021-2029]. The cloning and mapping of these genes together with the fine mapping of the three known genes indicates that the transcriptional map of this region is likely to be complete. Because this region frequently is altered in neoplasms and in the genetic disease Beckwith-Wiedemann syndrome, we carried out a mutational analysis in tumor cell lines and Beckwith-Wiedemann syndrome samples that resulted in the identification of genetic alterations in the BWR1A gene: an insertion that introduced a stop codon in the breast cancer cell line BT549 and a point mutation in the rhabdomyosarcoma cell line TE125-T. These results indicate that BWR1A may play a role in tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.